Navigation Links
Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado
Date:1/6/2011

LITTLE FALLS, N.J., Jan. 6, 2011 /PRNewswire/ -- Regenicin's (OTC Bulletin Board: RGIN) Chief Operating Officer, Chris Hadsall, recently received the 2010 Citizenship Award for his volunteer work with the VET Foundation and disabled veterans. Mr. Hadsall received the award at the VFW's 111th Annual Founders Day Banquet in December.  Hadsall joins a long list of notable citizens and groups bettering the lives of Veterans in the Colorado community. 

Mr. Hadsall served our country as a decorated Operations and Intelligence Officer for the U.S. Marine Corps, where his responsibilities included supervision of operations, logistics and communications for over 150 marines. During his career in the USMC, Mr. Hadsall helped establish the Wounded Warrior Program, which provides unique services to wounded servicemen and founded the VET Foundation, an organization committed to helping service disabled veterans transition out of the military.  As a wounded veteran himself, Mr. Hadsall has been awarded the Purple Heart as well as the Iraqi Freedom Medal for his service to our country.  

"We congratulate Chris on his VFW Citizenship Award for his volunteer work with the Vet Foundation," says Randall McCoy, CEO of Regenicin. "We are honored and proud to have such an experienced, well respected citizen and former Marine heading up the operations for Regenicin."

About Regenicin

Regenicin, Inc., (OTC Bulletin Board: RGIN) is a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is playing a critical role in the development of the therapeutic candidate, PermaDerm™, an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns.  The company is publicly traded with headquarters in Little Falls, NJ. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.

Safe Harbor Statement.  This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition.  A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission.  The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Regenicin(TM), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin Announces Closing of Private Placement Transaction
2. Regenicin Changes Its Ticker Symbol to RGIN.OB
3. Regenicin Presentation Now Available Online at RetailInvestorConferences.com
4. Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine
5. Regenicin to Present Live at RetailInvestorConferences.com on November 4th
6. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
7. Regenicin to Form Scientific Advisory Board
8. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
9. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
10. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
11. Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart IOT ... to get under way for the framework, which is designed to reduce the use ... to be transferred eventually to other industries that also require efficient IoT and management ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
(Date:2/16/2017)... Feb. 16, 2017   Biostage, Inc. (Nasdaq: ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, announced today the closing on February 15, 2017 ... of common stock and warrants to purchase 20,000,000 shares ... million. The offering was priced at $0.40 per share ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):